A Study of Avoralstat In Participants With Diabetic Macular Edema
← catalyst calendarSponsored by BioCryst Pharmaceuticals (industry) · BCRX — their whole pipeline →.
Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Na · None · Treatment
Enrollment
3actual
Sites
8
Countries
Australia, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Strategic decision
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-02 | actual | When the study began enrolling |
| Primary completion | 2026-04-17 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-04-17 | actual | The whole study's end, after follow-up |
| First posted | 2025-11-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Diabetic Macular Edema (DME)
Intervention
- Drug: avoralstat
Primary outcome
what the primary-completion date above is the date OFThe safety and tolerability of avoralstat in participants with DME. Incidence and severity of ocular (study eye) and systemic treatment emergent adverse events (TEAEs).
measured From screening through EOS (Week 24)
Permalink · BCRX's whole pipeline · Catalyst calendar · Every registered study · What changed